𝔖 Bobbio Scriptorium

✦ LIBER ✦

A TRIAL OF $beta;-NAPHTHYLDI-2-CHLOROETHYLAMINE (R48) IN LEUKqMIA, HODGKIN'S DISEASE, AND ALLIED DISEASES

✍ Scribed by MATTHEWS, W

Book ID: 122017068
Publisher: The Lancet
Year: 1950
Tongue: English
Weight: 874 KB
Volume: 255
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(50)90732-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TRIAL OF β-NAPHTHYL-DI-2-CHLOROETHYLAMIN

TRIAL OF β-NAPHTHYL-DI-2-CHLOROETHYLAMINE IN LEUKÆMIA, HODGKIN'S DISEASE, AND ALLIED DISORDERS

✍ Gardikas, C.; Wilkinson, JohnF. 📂 Article 📅 1951 🏛 The Lancet 🌐 English ⚖ 555 KB

A randomized trial of chemotherapy with

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

✍ J.-P. Glossmann; A. Josting; B. Pfistner; U. Paulus; A. Engert; German Hodgkin's 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 90 KB

O4-03-08: Efficacy and safety of MPC-786

O4-03-08: Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Aβ42-lowering agent, in Alzheimer’s disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study

✍ Gordon K. Wilcock; Sandra E. Black; Judith Haworth; Suzanne B. Hendrix; Mark Lau 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Clinical and pharmacokinetic evaluation

Clinical and pharmacokinetic evaluation of the selective D2 agonist, MK-458 in parkinson's disease (PD) : Neal R. Cutler, M.D., Scott A. Reines, M.D., Ph.D., Lewis F. McLean, Ph.D., John J. Sramek, Pharm. D., Arturo G. Porras, Ph.D., Elizabeth L. Hand, B.S. California Clinical Trials, Beverly Hills, CA 90211, and Merck Sharp & Dohme, West Point, PA 19486

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 267 KB